We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+11.07%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.52B
AUM Growth
+$425M
Cap. Flow
+$155M
Cap. Flow %
2.81%
Top 10 Hldgs %
32.71%
Holding
141
New
18
Increased
27
Reduced
28
Closed
15

Top Buys

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$109M
2
UTHR icon
United Therapeutics
UTHR
+$89M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$87.1M
4
BAX icon
Baxter International
BAX
+$79M
5
CI icon
Cigna
CI
+$41.9M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$57.1M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$47M
3
BLU
BELLUS Health Inc.
BLU
+$36.8M
4
PGNY icon
Progyny
PGNY
+$33.3M
5
SYK icon
Stryker
SYK
+$27.8M

Sector Composition

Rank Sector Weight
1 Healthcare 96.75%
2 Industrials 1.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JANX icon
51
Janux Therapeutics
JANX
$900M
$33.7M 0.61%
2,836,386
– –
IOVA icon
52
Iovance Biotherapeutics
IOVA
$2.02B
$33.1M 0.6%
4,707,458
– –
MRTX
53
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$33M 0.6%
913,650
– –
HZNP
54
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$32.5M 0.59%
316,400
+116,400
+58% +$12.3M
TVTX icon
55
Travere Therapeutics
TVTX
$5.12B
$32.5M 0.59%
2,118,100
+373,800
+21% +$6.8M
TELA icon
56
TELA Bio
TELA
$30.9M
$28.7M 0.52%
2,835,542
-192,000
-6% -$1.96M
AMGN icon
57
Amgen
AMGN
$211B
$28.3M 0.51%
127,300
+50,600
+66% +$11.7M
VERA icon
58
Vera Therapeutics
VERA
$2.33B
$28.2M 0.51%
1,756,800
+394,400
+29% +$3.56M
THRD
59
DELISTED
Third Harmonic Bio
THRD
$27.8M 0.5%
5,779,071
– –
ABCL icon
60
AbCellera Biologics
ABCL
$1.62B
$27M 0.49%
4,180,768
– –
KNTE
61
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$24.3M 0.44%
8,009,729
+2,866,100
+56% +$11M
TSVT
62
DELISTED
2seventy bio
TSVT
$24.2M 0.44%
2,391,628
– –
MRSN
63
DELISTED
Mersana Therapeutics
MRSN
$23.7M 0.43%
288,597
-71,860
-20% -$10.5M
QURE icon
64
uniQure
QURE
$2.74B
$23.7M 0.43%
2,064,455
– –
RAPT
65
DELISTED
RAPT Therapeutics
RAPT
$23.4M 0.42%
156,384
– –
FOLD
66
DELISTED
Amicus Therapeutics
FOLD
$23.3M 0.42%
1,856,400
+685,400
+59% +$8.13M
ALXO icon
67
ALX Oncology
ALXO
$261M
$21.6M 0.39%
2,871,000
– –
IMA
68
ImageneBio Inc
IMA
$65.3M
$20.9M 0.38%
265,514
– –
ACET icon
69
Adicet Bio
ACET
$76M
$20.2M 0.37%
520,134
+54,688
+12% +$4.83M
DBTX
70
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$19M 0.35%
4,945,192
– –
ARQT icon
71
Arcutis Biotherapeutics
ARQT
$3.49B
$18.2M 0.33%
1,914,479
– –
NPCE icon
72
Neuropace
NPCE
$483M
$18M 0.33%
4,012,281
– –
VTYX
73
DELISTED
Ventyx Biosciences
VTYX
$17.7M 0.32%
540,984
-44,016
-8% -$1.52M
CRVS icon
74
Corvus Pharmaceuticals
CRVS
$1.1B
$15.9M 0.29%
6,943,654
– –
FUSN
75
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$14.6M 0.26%
3,122,770
– –
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2023 Portfolio in Review

As of Q2 2023, OrbiMed held 141 positions worth $5.52B, up 8.3% from $5.09B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

OrbiMed's Q2 2023 filing shows 18 new, 27 increased, 28 reduced and 15 closed positions. Its largest new stake was ACELYRIN: 5,326,302 shares worth $111M. The largest sale was Bristol-Myers Squibb, an estimated $57.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Industrials.

  • OrbiMed's largest Q2 2023 buy was ACELYRIN: 5,326,302 shares worth $111M.
  • OrbiMed added most to Baxter International in Q2 2023, an estimated $79M increase.
  • OrbiMed's biggest Q2 2023 reduction was Bristol-Myers Squibb, cutting an estimated $57.1M.
  • OrbiMed fully exited Chinook Therapeutics, Inc. Common Stock in Q2 2023, selling an estimated $47M.
  • OrbiMed's ten largest holdings make up 33% of its $5.52B portfolio in Q2 2023.
  • OrbiMed opened 18 new positions and closed 15 in Q2 2023.
  • OrbiMed's portfolio value rose 8.3% quarter-over-quarter to $5.52B.

Based on OrbiMed's 13F filing for Q2 2023, filed 14 Aug 2023.